Evidence map›Paper›PMID 40387384›Full record

ArticleAmerican journal of hematology2025

Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis.

Foteini Theodorakakou, Despina Fotiou, Filia Apostolakou, Ioannis Papassotiriou, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Foteini TheodorakakouDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0001-6926-0351
Despina FotiouDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Filia ApostolakouDepartment of Clinical Biochemistry, "Aghia Sophia" Children's Hospital, Athens, Greece.
Ioannis PapassotiriouFirst Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Vasiliki SpiliopoulouDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Ioannis Ntanasis-StathopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0002-6328-9783
Panagiotis MalandrakisDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Magdalini MigkouDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Nikolaos KanelliasDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Evangelos Eleutherakis-PapaiakovouDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Erasmia PsimenouDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Asimina PapanikolaouDepartment of Haemopathology, Evangelismos Hospital, Athens, Greece.
Charikleia GakiopoulouFirst Department of Pathology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Smaragdi MarinakiClinic of Nephrology and Renal Transplantation, National and Kapodistrian University of Athens, School of Medicine, Laikon Hospital, Athens, Greece.
Stavroula GiannouliSecond Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Maria GavriatopoulouDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0002-6244-1229
Evangelos TerposDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Meletios-Athanasios DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0001-8990-3254
Efstathios KastritisDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0001-8191-5832

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystatin C (CysC) has emerged as a novel and potentially more reliable biomarker for the estimation of glomerular filtration in the general population in patients with various conditions. In AL amyloidosis, the current renal staging system and renal response criteria are based on proteinuria and creatinine-based eGFR. We explored the prognostic role of CysC and of estimation of eGFR based on CysC-based equations in a cohort of 195 patients with newly diagnosed AL amyloidosis with renal involvement. Baseline CysC level was strongly and independently associated with progression to dialysis, and CysC levels ≥ 1.9 mg/L can be used in combination with the current renal staging system to identify patients with different risk of progression to dialysis among renal stages 2 and 3. eGFR based on CysC performed at least similarly to eGFR based on creatinine alone (by CKD-EPI race free formula) and the cutoff of 30 mL/min/1.73 m

Indexed as

AmyloidosisCystatin CImmunoglobulin Light-chain AmyloidosisAgedBiomarkersCreatinineDisease ProgressionFemaleGlomerular Filtration RateHumansMaleMiddle AgedPrognosisRenal DialysisBiomarkersCreatinineCST3 protein, humanCystatin Ccystatin Cdialysisglomerular filtration ratekidneylight chain amyloidosis

Identifiers

PMID40387384
PMCPMC12232513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.